anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Conventional isotonic lipid emulsions containing essential  omega -3-fatty acids, e.g. in the form of EPA, can be converted only inadequately in vivo into triunsaturated eicosanoids because they are preferentially consumed in energy metabolism, i.e. oxidised. Combination of  omega -3-fatty acids or their physiologically acceptable esters with triglycerides of medium chain length results in the triglycerides of medium chain length being preferentially oxidised in the body, and the  omega -3-fatty acids being protected from rapid oxidation so that increased amounts of them are available for the formation of triunsaturated eicosanoids. The combination also has a protective effect on the liver. Isotonic lipid emulsions containing  omega -3-fatty acids are used, in particular, for parenteral administration in post-aggression metabolism associated with chronic inflammatory disorders and in neonatology and paediatrics.
Plasma salicylic acid concentrations should be periodically monitored during long-term treatment with salsalate to aid maintenance of therapeutically effective levels: 10 to 30 mg/100 mL. Toxic manifestations are not usually seen until plasma concentrations exceed 30 mg/100 mL (see OVERDOSAGE). Urinary pH should also be regularly monitored: sudden acidification, as from pH 6.5 to 5.5, can double the plasma level, resulting in toxicity.

Because serious GI tract ulcerations and bleeding can occur without warning symptoms, physicians should monitor for signs or symptoms of GI bleeding. Patients on long-term treatment with NSAIDs, should have their CBC and a chemistry profile checked periodically. If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, Salsalate tablet, USP should be discontinued.
A few cases of anaphylactic/anaphylactoid reactions are reported in the postmarketing use of LYLLANA. Involvement of skin (hives, pruritus, swollen lips-tongue-face) and either respiratory tract (respiratory compromise) or gastrointestinal tract (abdominal pain, vomiting) are noted. 

Angioedema involving eye/eyelid, face, larynx, pharynx, tongue and extremity (hands, legs, ankles, and fingers) with or without urticaria requiring medical intervention are reported in the postmarketing use of LYLLANA. Angioedema involving the tongue, glottis, or larynx, may result in airway obstruction. Do not give LYLLANA to any woman who develops angioedema during treatment with LYLLANA. 

Exogenous estrogens may exacerbate symptoms of angioedema in women with hereditary angioedema.

Consider whether the benefits of estrogen therapy outweigh the risks in such women.
Participants first received Memantine 10 mg capsule twice a day for 24 weeks. After a washout period of 4 weeks, they then received Placebo capsule (matching Memantine 10 mg capsule) twice a day for 24 weeks.
Epirubicin and Cyclophosphamide 600mg/m² for 4 times. Patients with HER2-positive tumors receive Trastuzumab and Pertuzumab.
Clinical trials have, in general, formally demonstrated the effectiveness and safety of various autologous therapies for the treatment of knee OA. Differences in the processing of autologous therapies can yield substantial differences in the resulting output. Thus, making generalizations regarding the effectiveness across these autologous therapies is more complicated. Each autologous therapy requires independent efficacy evaluation. nSTRIDE APS has been shown to decrease pain, increase function and have a favorable safety profile in a pilot trial. Further, demonstration of the treatment effects in patellofemoral osteoarthritis, an important subset of knee osteoarthritis is lacking. This study will evaluate a population of female patients with patellofemoral osteoarthritis in which treatment with other modalities provides limited/short lived relief with the hope that APS treatment will provide and extend relief to these patients. The study will document the treatment effects and timeline of treatment effects for nSTRIDE APS following a single injection (per symptomatic knee).
Participants received a 1000 mg intravenous (IV) infusion, on days 1 (split dose 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1 and day 1 of cycles 2 - 8, 21 day cycles. All participants received corticosteroids IV prior to the initial dose.
BACKGROUND: Catheter-related bladder discomfort (CRBD) and pain commonly arises postoperatively in patients who undergo intra-operative urinary catheterization. The study aims to demonstrate the effectiveness of intravenous lidocaine to prevent CRBD and postoperative pain in complex lumbar spinal surgery.
METHODS: Eighty male patients, aged 20-79 years, scheduled for elective fusion spine surgery at least two levels were randomly assigned to receive either intravenous lidocaine (1.5 mg/kg followed by 2 mg/kg/h) (Group L) or a parallel volume of normal saline (Group C). The primary outcome was incidence of moderate to severe CRBD in a postanesthetic care unit (PACU) between the two groups. Secondary outcomes included postoperative pain, 24-hour post operative opioid requirement, mild and moderate to severe CRBD at 1, 2, 6 and 24 h postoperatively, patient satisfaction on Global Perceived Effect Scale (GPES), and the adverse effects of lidocaine and surgical complications.
RESULTS: Group L showed a significantly lower incidence of moderate-to-severe CRBD compared to Group C in the PACU (P = 0.002) and at 1 h postoperatively (P = 0.039). Additionally, Group L experienced a significantly lower average pain scores compared to Group C at all time points (P < 0.001, P < 0.001, P = 0.001, P < 0.001 and P < 0.001 at 0, 1, 2, 6 and 24 h, respectively) and demonstrated a significantly reduced postoperative morphine requirement across all time intervals (P < 0.05). Group L also reported significantly higher satisfaction on GPES compared to group C (P < 0.001). No adverse outcome was observed in either group.
CONCLUSION: Intravenous lidocaine administration significantly reduced the incidence of moderate-to-severe CRBD at PACU and at 1 h postoperatively. Additionally, its use in complex spine surgery led to reductions in postoperative pain, opioid requirement, and improved patient satisfaction, without any observed side effects.
The present invention pertains to the field of medicine, more precisely to that of clinical immunology, and essentially relates to the production as well as to the use of a new complex preparation for immunoprophylaxis against various types of infections simultaneously. This invention essentially relates to the use of preparations for immunoprophylaxis against viral hepatitis B and D, tetanus and diphtheria. This invention also relates to a combined vaccine for immunoprophylaxis against viral hepatitis B ad D, tetanus and diphtheria, wherein said vaccine contains the antigens thereof as well as a builder. This vaccine is characterised in that it also contains the following members as antigens for an amount of 1 ml: an antigen of the hepatitis B virus (HBsAg) obtained by cultivating transformed cells from the strain S. cerevisiae VKPM Y-2203 in an amount of 5 to 10 νg; a purified and concentrated diphtheric anatoxin in an amount of 5 to 30 Lf; a purified and concentrated tetanic anatoxin in an amount of 5 to 10 EC; merthiolate in an amount of 0.01 ? 0.002 %; a hydroxide aluminium gel in an amount of 0.6 to 1.2 mg as converted into aluminium; and up to 1.0 ml of a pharmaceutically acceptable solvent. These preparations have a high seroconversion rate due to the mutual promoting action of the components used therein.
High-dose selenium is known to reduce systemic inflammatory responses through antioxidant and anti-inflammatory effects. Selenium has also been shown in pre-clinical studies to inhibit chemotherapy-induced peripheral neuropathy through reactive oxygen species mechanisms in cells. Therefore, the investigators aimed to confirm the effect of preventing high dose intravenous selenium prior to chemotherapy and to prevent neuropathy caused by chemotherapy. In this study, the investigators will identify the frequency and severity of CIPN according to World Health Organization (WHO) criteria. Also, the investigators will assess the patient's quality of life (QoL), evaluate the effects of the administration of inorganic selenium on CIPN and QoL, and confirm the safety of high-dose selenium. I would like to.
Non-invasive Ocular Drug Delivery Insert Technology The invention concerns an ocular insert which is a new biocompatible polymer-based controlled drug delivery system (CDDS) applicable to a variety of drugs and other compounds for the treatment of different ocular pathologies. This ocular insert allows releasing of at least one drug under suitable concentration levels during suitable periods of time. The device may be inserted in the lower or upper fornix conjunctiva, in a non-invasive way, meaning that the patient will be able to place the device himself, without intervention of medical specialized staff. The insert of the invention will release the drug in such a controlled rate that will allow the drug release up to 300 days by either a "Fickian" or a linear profile according to the intend purpose or pathology. The insert can be prepared with different shapes (spherical or spherical dome) and/or architectures (monolithic/layered either with or without a drug core) allowing the incorporation of at least one drug which can be released at different rates. The size, shape and design of the insert is adjusted in order to tune the drug(s) delivery profile(s) and to inhibit the risk of displacement or expulsion.
BACKGROUND: Residual breast tumors may remain after vacuum-assisted excisional biopsy (VAEB).
OBJECTIVE: To determine the incidence of residual breast tumors in patients after VAEB and the efficacy of magnetic resonance imaging (MRI) in detecting these tumors.
METHODS: This retrospective analysis examined patients who received VAEB before a diagnosis of breast cancer (BC) at our hospital from 2015 to 2019. The incidence of residual tumors after VAEB was determined by MRI and pathological examination. The diagnostic value of MRI in detecting residual tumors was determined for all patients and different subgroups. Logistic regression analysis was used to identify factors associated with residual tumors.
RESULTS: We examined 147 patients and obtained pathological samples from 146 patients, including 103 (70.5%) with residual tumors and 43 (29.5%) without residual tumors. The MRI examinations demonstrated the complete tumor resection rate was 48.9%. Compared to the pathological results, MRI had a positive predictive value of 77.8%, negative predictive value of 48.8%, specificity of 65.6%, and sensitivity of 60.7%. Further analysis indicated that MRI had moderate accuracies for patients with stage pT-1 (71.9%), stage pTNM-IA (73.1%), and luminal B subtype (78.3%). Binary logistic regression analysis showed that the risk of tumor residue correlated with the pathological stage.
CONCLUSION: Tumor residue is common after VAEB, and MRI has limited accuracy in detecting these residual tumors. However, for small breast tumors and luminal B subtype BC, MRI had higher accuracy in the detection of residual tumors. The risk of tumor residue is closely associated with the pathological stage.
BACKGROUND Breast pain, prevalent among women of reproductive age, varies during menstrual cycles and is influenced by sociodemographic and clinical factors. This study aimed to assess these demographic and clinical variables in women with breast pain, considering the spatial distinctions between urban and rural locations. MATERIAL AND METHODS This retrospective study included 730 women presenting with mastalgia between 2010 and 2023. The study evaluated patient demographics, pain characteristics (eg, breast pain duration, site, quadrant-based localization, and radiation of breast pain), radiologic findings, and the presence of comorbid medical conditions. RESULTS There were 498 patients in the urban group and 232 patients in the rural group. Among the radiologic findings, the rate of mastitis was higher in the rural group (P<0.05). Regarding the localization of breast pain within the quadrants, left breast upper-inner (LUI) quadrant pain was more common in the rural group (P=0.014). Regarding comorbid medical conditions, the prevalence of gastrointestinal system disease was higher in the rural group (P=0.009). Using logistic regression analysis, gastrointestinal disease was determined to be a significant independent risk factor for increased LUI quadrant pain in the rural group (odds ratio [OR]: 3.132, P=0.014), while pre-existing thyroid disease (OR: 2.482, P=0.004), hypertension (OR: 2.534, P=0.006), and radiologic evidence of ductal ectasia (OR: 2.878, P=0.03) were independent risk factors in the urban group. CONCLUSIONS Patient outcomes may be improved by a tailored, population-based approach to mastalgia patients in rural and urban locations focused on their radiologic findings and comorbid medical conditions.
ETHNOPHARMACOLOGICAL RELEVANCE: Tenuigenin (TNG) is an extract obtained from Polygalae Radix. It possesses anti-inflammatory, antioxidant, and neuroprotective properties. However, the potential mechanism of TNG in intracerebral hemorrhage (ICH) has not been well studied.
AIM OF THE STUDY: In the present study, we aimed to identify the prospective mechanism of TNG in treating ICH.
MATERIALS AND METHODS: A total of 120 mice were divided into five groups: Sham group, ICH + vehicle group, ICH + TNG(8 mg/kg), ICH + TNG(16 mg/kg), and ICH + TNG(32 mg/kg). The modified Garcia test and beam walking test were carried out at 24 h and 72 h after ICH. Brain water content, haematoma volume and hemoglobin content examinations were performed at 72 h after ICH. TMT-based quantitative proteomics combined with bioinformatics analysis methods was used to distinguish differentially expressed proteins (DEPs) to explore potential pharmacological mechanisms. Western blotting was performed to validate representative proteins.
RESULTS: Our results showed that the optimal dose of TNG was 16 mg/kg, which could markedly improve neurological functions, and reduce cerebral oedema, haematoma volume and hemoglobin levels 72 h after ICH. A total of 404 DEPs (353 up-and 51 downregulated) were identified in the ICH + vehicle vs. sham group, while 342 DEPs (306 up-and 36 downregulated) and 76 DEPs (28 up-and 48 downregulated) were quantified in the TNG vs. sham group and TNG vs. ICH + vehicle group, respectively. In addition, a total of 26 DEPs were selected according to strict criteria. Complement and coagulation cascades were the most significantly enriched pathways, and two proteins (MBL-C and Car1) were further validated as hub molecules.
CONCLUSIONS: Our results suggested that the therapeutic effects of TNG on ICH were closely associated with the complement system, and that MBL-C and Car1 might be potential targets of TNG for the treatment of ICH.
Bispecific binding proteins that bind IL-1[beta] or IL-1R and a checkpoint protein are provided, together with methods of making the proteins. The checkpoint protein may be PD-1 or PD-L1. The binding proteins may have immunoglobulin-like structures that contain human Fab or scFv domains. A novel bispecific antibody format is provided. Methods of making the binding proteins are provided, together with pharmaceutical compositions containing the proteins. The binding proteins and pharmaceutical compositions may be used for treating or preventing diseases such as cancer.
BACKGROUND: To report a case of unusual presentation of retinochoroiditis caused by Rickettsia typhi in a patient without prior uveitis.
CASE PRESENTATION: In this case, we describe a 24-year-old male soldier with no previous eye disease, who was referred to our ophthalmology department due to bilateral retinochoroiditis and vitritis. The patient initially presented with a paracentral scotoma in his right eye persisting for 7 days and scattered dark spots in his left eye for 2 days in June 2023. Preceding these ocular symptoms, he experienced a two-week episode of fever, headaches, night sweats, and rapid weight loss of 10 kg. A transient rash covered his body briefly. His mother had a history of recurrent eye inflammation. Physical examination revealed bilateral keratic precipitates on the lower corneal periphery, 1 + anterior vitreous cells, small retinal lesions and mild optic discs elevation. Fluorescein angiography indicated mild discs hyperfluorescence, and the clinically visible round punctate lesions on OCT showed inner retinal hyper-reflective lesion with a depth till outer plexiform layer possibly suggestive of a retinitis lesion. Laboratory tests were normal except thrombocytosis, elevated ESR, liver enzymes and ACE levels, with positive Rickettsia typhi serology tests. Rheumatology and infectious disease consultations ruled out autoimmune diseases, confirming Rickettsia typhi infection. Treatment included systemic doxycycline and prednisone, with improvement of visual acuity, ocular symptoms, OCT abnormalities and resolution of inflammation. Prednisone was discontinued, and after two months, additional improvement was seen clinically, with preserved retinal structures on OCT.
CONCLUSION: This study explores retinochoroiditis as a rare ocular presentation of Rickettsia typhi, an unusual infection in the Middle East. Previously reported ocular manifestations include conjunctivitis, vitritis, post infectious optic neuropathy and a few cases of uveitis. Ocular symptoms followed systemic illness, highlighting the need for awareness among clinicians. Diagnosis relies on seroconversion, with fluorescein angiography and OCT aiding in assessment. Empiric doxycycline and systemic corticosteroid therapy is recommended. Ocular symptoms resolved in two months. Awareness of these ocular manifestations is essential for timely diagnosis and management. Further research is needed to fully understand this aspect of murine typhus.
FIELD: medicine. SUBSTANCE: method involves applying additional treatment using among others physical factors provided with Milta device in combination with complex therapy including anti-arrhythmic medicaments like adenosine pyrophosphate inhibitors. The treatment involves applying complex pulsating laser radiation and continuous infrared radiation in 850-950 nm bandwidth in combination with constant magnetic field. The treatment is applied to known acupuncture points in known mode. Finger massage techniques are applied to the same points in combination with the treatment. EFFECT: enhanced effectiveness of treatment. 10 tbl
PURPOSE: A composition containing Homonoia riparia Lour. extract for preventing and treating obesity, hyperlipidemia, and metabolic syndrome is provided to suppress pancreatic lipase and phosphodiesterase(PDE) actions. CONSTITUTION: A pharmaceutical composition for preventing or treating obesity contains Homonoia riparia Lour. extract as an active ingredient. A pharmaceutical composition for preventing or treating hyperlipidemia or metabolic syndrome contains Homonoia riparia Lour. extract as an active ingredient. The Homonoia riparia Lour. extract is isolated using water, alcohol of C1-C4, or mixture solvent thereof. A functional food for preventing or treating hyperlipidemia and metabolic syndrome contains Homonoia riparia Lour. extract as an active ingredient.
Part B-Arm 1 will include approximately 20 patients with pancreatic cancer and other solid tumors. This subject group will receive RC118-ADC and Toripalimab (3.0mg/kg) Day 1 of every 14-day cycle. The starting dose of RC118-ADC for expansion will be derived from the RP2D determined during Part A.
Infectious disease is the single biggest cause of death worldwide. New infectious agents, such as the SARS-CoV-2, require investigation to understand pathogen biology and pathogenesis in the host. In order to develop a mechanistic understanding of disease processes, such that risk factors for severe illness can be identified and treatments can be developed, it is necessary to understand pathogen characteristics associated with virulence, the replication dynamics and in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of antimicrobial or host directed therapies, the transmission dynamics, and factors underlying individual susceptibility.

At Oslo University Hospital, an observational study on the newly discovered emerging SARS- CoV-2, the coronavirus that causes COVID-19 infection has started. The study has been approved by the Regional Ethics Committee, so that inclusion of confirmed COVID-19 cases admitted at the hospital can start immediately including the first patients needing hospitalisation. The plan is to include more hospitals in other parts of Norway, starting with inclusion of Akershus University Hospital, Vestre Viken Drammen Hospital and Østfold Hospital. The study is anticipated to provide much needed data on the course of the COVID-19 infection, as well as generating knowledge about the virus and its transmission.
In the experimental arms, the woman will be asked to collect a vaginal sample with the Evalyn® Brush or a urine sample with the Colli-PeeTM. Women shall receive this self-sampling device directly from the GP or shall pick it up at a close by pharmacist with a prescription of the GP. In four GP practices (1, 2, 5, 6) the patient has to collect the SS preferentially in the GP practice (at home if the GP practice is not well equipped) whereas in the other four GP practices (3, 4, 7, 8), the patient has to collect the SS at home and send it to the laboratory by using a prepaid envelope.
Methods of treating lung proliferative vascular disorders by administering an antiproliferative agent are provided. A preferred antiproliferative agent is a HMG-CoA reductase inhibitor, preferably simvastatin. Vascular occlusion in the pulmonary arteries of the patient is reduced as a result of the treatment through a reduction in neointimal hyperplasia and medial hypertrophy, and the restoration of normal endothelial cell function. The treatment also results in a reversal of right side cardiac hypertrophy. Lung proliferative vascular disorders that can be treated include primary pulmonary hypertension, secondary pulmonary hypertension, Eisenmenger's syndrome, chronic thromboembolic disease, pulmonary fibrosis, obliterative bronchiolitis, or lymphangioleiomyomatosis. Dosages and pharmaceutical formulations are provided.